Marked response to single agent trastuzumab in a patient with metastatic HER-2 gene amplified rectal cancer

Cancer Investigation

Volumn 29, Issue 7, 2011, Pages 456-459

  Sorscher, Steven M ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Colorectal Anal cancer; Gene expression; Treatment

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; TRASTUZUMAB;

ADRENAL METASTASIS; ADULT; ARTICLE; BONE BIOPSY; BONE METASTASIS; CANCER PATIENT; CANCER RADIOTHERAPY; CASE REPORT; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL ENDOSCOPY; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; HUMERUS FRACTURE; IMMUNOHISTOCHEMISTRY; LOADING DRUG DOSE; MONOTHERAPY; ONCOGENE NEU; PARAAORTIC LYMPH NODE; PRIMARY TUMOR; PRIORITY JOURNAL; RECTUM CANCER; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RECTAL NEOPLASMS;

EID: 79960189638     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.590569     Document Type: Article

References (8)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogenes. Science 1987;234:177-182. (Pubitemid 17231334)
2. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart S, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer. J Clin O. 2002;20(3): 719.
3. Romand EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Vissher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Momounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N, Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer. N England J Med 2005;353(16):1673.
4. Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, Hill J, Lehle M, Feyereislova A, Bang Y. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer(GC). J Clin Oncol 2009;27:18s, (suppl;abstr LBA 4509).
5. Ramanthan RK, Hwang JJ, Zamboni WC, Sinicrope FA, Safran H, Wong MK, Earle M, Brufsky A, Evans T, Troetschel M, Walko C, Day R, CheHX, Finkelstein S. Low expression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan therapy. A phase II trial. Cancer Invest 2004;22(6):858-865. (Pubitemid 39665350)
6. Kavanagh DO, Chambers G, O'Grady L, Barry KM, Waldron RP, Bennani F, Eustace PW, Tobbia I. Is Overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer 2009;9:1 doi:10.1186/1471-2407-9-1.
7. Zhou C, Wu Y-L, Chen G, Feng J, Liu X, Wang C, Zhang S, Wang J, Zhou S, Ren S. Efficacy results from the randomized phase III optimal (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small-cell lung cancer (NSCLC) patients (pts) with EGFR avtivating mutations. Ann Oncol 2010;21(suppl; abstr LBA 13).
8. Miller DV, Dueck AC, Tenner KS, Jenkins RB, Kaufman PA, DavidsonNE,Dakhil SR,MartinoS, RoyV,PerezEA.Benefitof adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial. J Clin Oncol 2009;27:15s, (suppl; abstr 520).